In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...

Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

Immune kinases including, JAK1, JAK2, JAK3, TYK2 and BTK have shown clinical effects ... develop and commercialize small-molecule inhibitors of TAK1. June 20, 2024 Aqilion announced that Aqilion and ...

MLN0128 (formerly known as INK128) is a novel, orally active mTOR kinase inhibitor currently in clinical development. Here, we evaluated MLN0128 in preclinical models of B-cell acute lymphoblastic ...

Sugammadex (Bridion; Merck) is a small-molecule oligosaccharide, also known as a modified gamma cyclodextin, that was approved by the FDA in 2015 to reverse the anesthesia-induced neuromuscular ...

and Merck & Co are making substantial strides in the creation of cutting-edge therapies designed to enhance symptom management and improve long-term outcomes for CU patients. Furthermore, the ...

He says, if confirmed, he can still earn referral fees from a firm suing Merck. In 2020, as a pandemic raged across the globe, Robert F. Kennedy Jr. took to social media to appeal to his hundreds ...

Additionally, advancements in precision medicine and targeted therapies, including HER2 inhibitors and hormone therapies, are improving outcomes while minimizing side effects. According to the ...